187 related articles for article (PubMed ID: 37696281)
1. Conventional versus hypofractionated postmastectomy proton radiotherapy in the USA (MC1631): a randomised phase 2 trial.
Mutter RW; Giri S; Fruth BF; Remmes NB; Boughey JC; Harless CA; Ruddy KJ; McGee LA; Afzal A; Gao RW; Shumway DA; Vern-Gross TZ; Villarraga HR; Kenison SL; Kang Y; Wong WW; Stish BJ; Merrell KW; Yan ES; Park SS; Corbin KS; Vargas CE
Lancet Oncol; 2023 Oct; 24(10):1083-1093. PubMed ID: 37696281
[TBL] [Abstract][Full Text] [Related]
2. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
3. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A
Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529
[TBL] [Abstract][Full Text] [Related]
4. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
[TBL] [Abstract][Full Text] [Related]
5. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
[TBL] [Abstract][Full Text] [Related]
6. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial.
Wang SL; Fang H; Song YW; Wang WH; Hu C; Liu YP; Jin J; Liu XF; Yu ZH; Ren H; Li N; Lu NN; Tang Y; Tang Y; Qi SN; Sun GY; Peng R; Li S; Chen B; Yang Y; Li YX
Lancet Oncol; 2019 Mar; 20(3):352-360. PubMed ID: 30711522
[TBL] [Abstract][Full Text] [Related]
7. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Brand DH; Tree AC; Ostler P; van der Voet H; Loblaw A; Chu W; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Henderson D; Brown S; Cruickshank C; Burnett S; Duffton A; Griffin C; Hinder V; Morrison K; Naismith O; Hall E; van As N;
Lancet Oncol; 2019 Nov; 20(11):1531-1543. PubMed ID: 31540791
[TBL] [Abstract][Full Text] [Related]
8. One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT.
Brunt AM; Haviland JS; Wheatley DA; Sydenham MA; Bloomfield DJ; Chan C; Cleator S; Coles CE; Donovan E; Fleming H; Glynn D; Goodman A; Griffin S; Hopwood P; Kirby AM; Kirwan CC; Nabi Z; Patel J; Sawyer E; Somaiah N; Syndikus I; Venables K; Yarnold JR; Bliss JM;
Health Technol Assess; 2023 Nov; 27(25):1-176. PubMed ID: 37991196
[TBL] [Abstract][Full Text] [Related]
9. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.
Incrocci L; Wortel RC; Alemayehu WG; Aluwini S; Schimmel E; Krol S; van der Toorn PP; Jager H; Heemsbergen W; Heijmen B; Pos F
Lancet Oncol; 2016 Aug; 17(8):1061-1069. PubMed ID: 27339116
[TBL] [Abstract][Full Text] [Related]
10. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Dearnaley D; Syndikus I; Mossop H; Khoo V; Birtle A; Bloomfield D; Graham J; Kirkbride P; Logue J; Malik Z; Money-Kyrle J; O'Sullivan JM; Panades M; Parker C; Patterson H; Scrase C; Staffurth J; Stockdale A; Tremlett J; Bidmead M; Mayles H; Naismith O; South C; Gao A; Cruickshank C; Hassan S; Pugh J; Griffin C; Hall E;
Lancet Oncol; 2016 Aug; 17(8):1047-1060. PubMed ID: 27339115
[TBL] [Abstract][Full Text] [Related]
11. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Wilkins A; Mossop H; Syndikus I; Khoo V; Bloomfield D; Parker C; Logue J; Scrase C; Patterson H; Birtle A; Staffurth J; Malik Z; Panades M; Eswar C; Graham J; Russell M; Kirkbride P; O'Sullivan JM; Gao A; Cruickshank C; Griffin C; Dearnaley D; Hall E
Lancet Oncol; 2015 Dec; 16(16):1605-16. PubMed ID: 26522334
[TBL] [Abstract][Full Text] [Related]
12. Influence of Hypofractionated Versus Conventional Fractionated Postmastectomy Radiation Therapy in Breast Cancer Patients With Reconstruction.
Kim DY; Park E; Heo CY; Jin US; Kim EK; Han W; Shin KH; Kim IA
Int J Radiat Oncol Biol Phys; 2022 Feb; 112(2):445-456. PubMed ID: 34610389
[TBL] [Abstract][Full Text] [Related]
13. Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial.
Guadagnolo BA; Bassett RL; Mitra D; Farooqi A; Hempel C; Dorber C; Willis T; Wang WL; Ratan R; Somaiah N; Benjamin RS; Torres KE; Hunt KK; Scally CP; Keung EZ; Satcher RL; Bird JE; Lin PP; Moon BS; Lewis VO; Roland CL; Bishop AJ
Lancet Oncol; 2022 Dec; 23(12):1547-1557. PubMed ID: 36343656
[TBL] [Abstract][Full Text] [Related]
14. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial.
Dearnaley D; Syndikus I; Sumo G; Bidmead M; Bloomfield D; Clark C; Gao A; Hassan S; Horwich A; Huddart R; Khoo V; Kirkbride P; Mayles H; Mayles P; Naismith O; Parker C; Patterson H; Russell M; Scrase C; South C; Staffurth J; Hall E
Lancet Oncol; 2012 Jan; 13(1):43-54. PubMed ID: 22169269
[TBL] [Abstract][Full Text] [Related]
15. Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial.
King MT; Link EK; Whelan TJ; Olivotto IA; Kunkler I; Westenberg AH; Gruber G; Schofield P; Chua BH;
Lancet Oncol; 2020 May; 21(5):685-698. PubMed ID: 32203696
[TBL] [Abstract][Full Text] [Related]
16. Hypofractionation for clinically localized prostate cancer.
Hickey BE; James ML; Daly T; Soh FY; Jeffery M
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD011462. PubMed ID: 31476800
[TBL] [Abstract][Full Text] [Related]
17. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial.
Tree AC; Ostler P; van der Voet H; Chu W; Loblaw A; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Armstrong J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Duffton A; Brand DH; Henderson D; Morrison K; Brown S; Pugh J; Burnett S; Mahmud M; Hinder V; Naismith O; Hall E; van As N;
Lancet Oncol; 2022 Oct; 23(10):1308-1320. PubMed ID: 36113498
[TBL] [Abstract][Full Text] [Related]
18. Hypofractionated Postmastectomy Radiation Therapy Is Safe and Effective: First Results From a Prospective Phase II Trial.
Khan AJ; Poppe MM; Goyal S; Kokeny KE; Kearney T; Kirstein L; Toppmeyer D; Moore DF; Chen C; Gaffney DK; Haffty BG
J Clin Oncol; 2017 Jun; 35(18):2037-2043. PubMed ID: 28459606
[TBL] [Abstract][Full Text] [Related]
19. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.
Haviland JS; Owen JR; Dewar JA; Agrawal RK; Barrett J; Barrett-Lee PJ; Dobbs HJ; Hopwood P; Lawton PA; Magee BJ; Mills J; Simmons S; Sydenham MA; Venables K; Bliss JM; Yarnold JR;
Lancet Oncol; 2013 Oct; 14(11):1086-1094. PubMed ID: 24055415
[TBL] [Abstract][Full Text] [Related]
20. External beam radiation dose escalation for high grade glioma.
Khan L; Soliman H; Sahgal A; Perry J; Xu W; Tsao MN
Cochrane Database Syst Rev; 2020 May; 5(5):CD011475. PubMed ID: 32437039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
